Results 131 to 140 of about 20,079 (290)

Combination therapy of varenicline and bupropion in smoking cessation: A meta-analysis of the randomized controlled trials

Comprehensive Psychiatry, 2019
Background: The effects of the combination therapy of varenicline and bupropion in smoking cessation are still controversial. Methods: Databases including PubMed, EMBASE, Cochrane Library and Web of Science were scanned without time and language ...
Zhaoshuang Zhong, Shijie Zhao, Yan Zhao, Shuyue Xia   +3 more
doaj   +1 more source

Helping Smokers Quit: State Cessation Coverage [PDF]

, 2008
Analyzes state health insurance coverage for treatments to quit smoking and how coverage through state Medicaid, state employee health plans, private insurance, and "quitlines" saves states healthcare costs.

core  

The Economic Impact of Smoking and of Reducing Smoking Prevalence: Review of Evidence [PDF]

BACKGROUND: Tobacco smoking is the cause of many preventable diseases and premature deaths in the UK and around the world. It poses enormous health- and non-health-related costs to the affected individuals, employers, and the society at large.
Brown, AK, Ekpu, VU
core   +1 more source

Varenicline: Implications for the Field

Journal of Smoking Cessation, 2007
AbstractVarenicline tartrate (Champix) is the first in a new class of therapy for smoking cessation and has been available on NHS prescription since December 2006. It has received approval from The National Institute for Health and Clinical Excellence (NICE) and the Scottish Medicines Consortium and NICE final guidance was issued in July 2007 ...
openaire   +2 more sources

Nicotinic receptors [PDF]

, 2014
Regulation of normal or abnormal behaviour is critically controlled by the central serotonergic systems. Recent evidence has suggested that serotonin (5-HT) neurotransmission dysfunction contributes to a variety of pathological conditions, including ...
A Auclair, A Beyeler, A Coppen, A Dahlstrom, A Fletcher, A Fletcher, A Gobert, A Jain, A Markou, A Pazos, AC Farley, AJ Grottick, AJ Grottick, AM Batman, AS Brown, AV Prochazka, B Chang, B Lendvai, BB Brodie, BL Jacobs, BM Twarog, BR Cooper, C Cirillo, C Nocjar, C Reperant, CP Müller, D Herve, D Hoyer, D Hoyer, D Kooy van der, D Quarta, DE Nichols, DJ Balfour, DJ Hayes, DL Murphy, DL Willins, DM Tomkins, DV Herin, E Costa, E Esposito, E Quattrocki, EB Ribeiro, EC Azmitia, ED Levin, ED Levin, EJ Bockstaele Van, EJ Bockstaele Van, EJ Mills, F Jenck, G Chevalier, G Chiara Di, G Cucchiaro, G Cucchiaro, G Engberg, G Giovanni Di, G Giovanni Di, G Giovanni Di, G Giovanni Di, G Giovanni Di, G Giovanni Di, G Giovanni Di, G Giovanni Di, G Porras, G Porras, GA Higgins, GA Higgins, GA Higgins, GA Kennett, GA Kennett, GF Koob, GW Dalack, H Khalki, H Moukhles, H Rollema, H Rollema, H Rollema, H Takahashi, HD Mansvelder, J Arnt, J Dong, J Hannon, JA Ascher, JE Anderson, JE Slemmer, JF Cryan, JH Thompson, JK Abrams, JL Neisewander, JR Martin, JW Coe, K Guillem, K Touiki, KD Alex, KG Baker, KH Thomas, KJ Clemens, KL Summers, L Galindo-Charles, L Pozzi, LA Pockros, LL McMahon, M Bubser, M Costa, M Dols, M Giorgetti, M Pierucci, M Pompeiano, M Reuben, M Zaniewska, M Zaniewska, M Zaniewska, MD Doherty, ME Benwell, MF O'Neill, MJ Bubar, MJ Bubar, MJ Eisenberg, MJ Millan, MM Rapport, N Corvaja, N Maurice, NA Rigotti, NB Edwards, NG Schneider, NM Barnes, OT Phillipson, P Deurwaerdere De, P Deurwaerdere De, P Enkhbaatar, P Olausson, P Olausson, P Seth, PA Crooks, PBS Clarke, PH Hutson, PJ Fletcher, PJ Fletcher, PJ Fletcher, PJ Kenny, PJ Kenny, PM Whitaker-Azmita, RD Schwartz, RF Mucha, RM Bowker, RM Bowker, RS Bitner, RS Bitner, S Hjorth, S Mihailescu, S Navailles, S Prisco, SG Matta, SJ Bonasera, SM Hall, SM Hall, SP Ji, SP Ranade, TA Shahan, V Cornea-Hébert, V Erspamer, V Hillegaart, V Matteo Di, V Matteo Di, V Matteo Di, V Matteo Di, V Matteo Di, V Matteo Di, V Matteo Di, W Feldberg, WA Corrigall, X Li, Y Takada, Z Ma, ZJ Yu   +173 more
core   +1 more source

Differentiating the primary reinforcing and reinforcement-enhancing effects of varenicline in a 2-lever, rat self-administration paradigm [PDF]

, 2013
Nicotine (NIC) has two reinforcement-related effects that may contribute to dependence: 1) NIC acts as a primary reinforcer, and 2) NIC, non-associatively, enhances reinforcement from concur- rently available nonpharmacological stimuli. Varenicline (VAR),
Levin, Melissa
core  

Probleme mit Vareniclin [PDF]

pharma-kritik, 2011
N ...
openaire   +2 more sources

Four patients with a history of acute exacerbations of COPD: implementing the CHEST/Canadian Thoracic Society guidelines for preventing exacerbations [PDF]

, 2015
This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if ...
A Singanayagam, AJ Crockett, AL Ries, AM Yohannes, C Fletcher, CE Bucknall, CM Fletcher, CP Hersh, D Brooks, DD Marciniuk, F Maltais, FA Cleutjens, G Guyatt, GJ Criner, J Chong, J Pynoos, J Strijbos, JJ Soler-Cataluna, JW Dodd, K Gruffydd-Jones, K Rockwood, K Rockwood, KH Groenewegen, L Cheyne, L Lahousse, L Puente-Maestu, LP Fried, LS Bickford, M Guell, M Stickland, M Zwerink, MM Ball, P Almagro, PG Gibson, PW Jones, S Hull, SK Park, SP Newman, T Bodenheimer, T Lee, TM Wilkinson, VS Fan, World Health Organization, Y Lacasse   +43 more
core   +1 more source

Drug-induced liver injury due to varenicline: a case report

BMC Gastroenterology, 2012
Background Liver injury due to prescription and nonprescription medications is an expanding public health concern in the United States, with drug-induced liver injury (DILI) being the single most common reason for regulatory actions instituted by the ...
Sprague David, Bambha Kiran
doaj   +1 more source

Efficacy of Varenicline, an α4β2 Nicotinic Acetylcholine Receptor Partial Agonist, vs Placebo or Sustained-Release Bupropion for Smoking Cessation: A Randomized Controlled Trial—Correction [PDF]

, 2006

openalex   +1 more source